Display options
Cite
Pandurangan AK, Kumar SA, Dharmalingam P, et al. Luteolin, a bioflavonoid inhibits azoxymethane-induced colon carcinogenesis: Involvement of iNOS and COX-2. Pharmacogn Mag. 2014;10:S306-10doi: 10.4103/0973-1296.133285.
Pandurangan, A. K., Kumar, S. A., Dharmalingam, P., & Ganapasam, S. (2014). Luteolin, a bioflavonoid inhibits azoxymethane-induced colon carcinogenesis: Involvement of iNOS and COX-2. Pharmacognosy magazine, 10S306-10. https://doi.org/10.4103/0973-1296.133285
Pandurangan, Ashok Kumar, et al. "Luteolin, a bioflavonoid inhibits azoxymethane-induced colon carcinogenesis: Involvement of iNOS and COX-2." Pharmacognosy magazine vol. 10 (2014): S306-10. doi: https://doi.org/10.4103/0973-1296.133285
Pandurangan AK, Kumar SA, Dharmalingam P, Ganapasam S. Luteolin, a bioflavonoid inhibits azoxymethane-induced colon carcinogenesis: Involvement of iNOS and COX-2. Pharmacogn Mag. 2014 Apr;10:S306-10. doi: 10.4103/0973-1296.133285. PMID: 24991108; PMCID: PMC4078326.
Copy Download .nbib Format: NLM
Share it on

Pharmacogn Mag. 2014 Apr;10:S306-10. doi: 10.4103/0973-1296.133285.

Luteolin, a bioflavonoid inhibits azoxymethane-induced colon carcinogenesis: Involvement of iNOS and COX-2.

Pharmacognosy magazine

Ashok Kumar Pandurangan, Suresh Ananda Sadagopan Kumar, Prakash Dharmalingam, Sudhandiran Ganapasam

Affiliations

  1. Department of Biochemistry, University of Madras, Guindy Campus, Chennai, India.

PMID: 24991108 PMCID: PMC4078326 DOI: 10.4103/0973-1296.133285

Abstract

Colon cancer (CRC) is a serious health problem through worldwide. Development of novel drug without side effect for this cancer was crucial. Luteolin (LUT), a bioflavonoid has many beneficial effects such as antioxidant, anti-inflammatory, anti-proliferative properties. Azoxymethane (AOM), a derivative of 1, 2-Dimethyl hydrazine (DMH) was used for the induction of CRC in Balb/C mice. CRC was induced by intraperitoneal injection of AOM to mice at the dose of 15 mg/body kg weight for 3 weeks. Mouse was treated with LUT at the dose of 1.2 mg/body kg weight orally until end of the experiment. The expression of inducible nitric oxide synthase (iNOS) and cyclooxygense (COX)-2 were analyzed by RT-PCR and immunohistochemistry. The expressions of iNOS and COX-2 were increased in the case of AOM induction. Administration of LUT effectively reduced the expressions of iNOS and COX-2. The present study revealed that, LUT suppresses both iNOS and COX-2 expressions and act as an anti-inflammatory role against CRC.

Keywords: Azoxymethane; COX-2; Luteolin; colon cancer; iNOS

References

  1. World J Gastroenterol. 2005 Jan 14;11(2):204-7 - PubMed
  2. N Engl J Med. 1995 Sep 7;333(10):609-14 - PubMed
  3. Bull World Health Organ. 1990;68(3):377-85 - PubMed
  4. Carcinogenesis. 1999 Apr;20(4):641-4 - PubMed
  5. Asian Pac J Cancer Prev. 2012;13(4):1569-73 - PubMed
  6. Am J Clin Nutr. 2002 Sep;76(3):560-8 - PubMed
  7. Cell. 1995 Nov 3;83(3):493-501 - PubMed
  8. J Ethnopharmacol. 1996 Aug;53(2):57-63 - PubMed
  9. Cancer Res. 1998 Jan 15;58(2):362-6 - PubMed
  10. Annu Rev Nutr. 2002;22:19-34 - PubMed
  11. Biomed Pharmacother. 2008 Nov;62(9):590-7 - PubMed
  12. Cancer Res. 1997 Apr 1;57(7):1233-7 - PubMed
  13. Biochem Pharmacol. 2006 Oct 16;72(8):1010-21 - PubMed
  14. J Natl Cancer Inst. 1998 Oct 21;90(20):1529-36 - PubMed
  15. Lancet. 1993 Feb 20;341(8843):465-6 - PubMed
  16. Life Sci. 2007 Nov 30;81(23-24):1602-14 - PubMed
  17. Eur J Pharmacol. 2006 Jul 10;541(1-2):95-105 - PubMed
  18. Cancer Res. 2000 Jan 15;60(2):293-7 - PubMed
  19. Cancer Res. 1996 Oct 1;56(19):4424-9 - PubMed
  20. Thyroid. 1999 Apr;9(4):369-76 - PubMed
  21. Annu Rev Med. 2002;53:35-57 - PubMed
  22. Invest New Drugs. 2011 Apr;29(2):273-84 - PubMed
  23. Endocr Regul. 2001 Mar;35(1):53-9 - PubMed
  24. Cancer Res. 1998 Jan 15;58(2):334-41 - PubMed
  25. Curr Cancer Drug Targets. 2004 Feb;4(1):29-42 - PubMed
  26. J Nutr. 2003 Oct;133(10):3248S-3254S - PubMed
  27. Fitoterapia. 2004 Sep;75(6):592-5 - PubMed
  28. Carcinogenesis. 2001 Sep;22(9):1557-60 - PubMed
  29. Cancer Epidemiol Biomarkers Prev. 2003 May;12(5):391-400 - PubMed
  30. Asian Pac J Cancer Prev. 2013;14(4):2201-5 - PubMed
  31. CA Cancer J Clin. 2004 May-Jun;54(3):150-80 - PubMed
  32. N Engl J Med. 1991 Dec 5;325(23):1593-6 - PubMed
  33. Environ Mol Mutagen. 2004;44(1):26-35 - PubMed
  34. Planta Med. 2007 Mar;73(3):221-6 - PubMed
  35. Am J Pathol. 2003 Mar;162(3):793-801 - PubMed
  36. Cancer Lett. 1992 Dec 24;67(2-3):207-13 - PubMed
  37. Lancet Oncol. 2001 Mar;2(3):149-56 - PubMed
  38. Life Sci. 2001 Sep 7;69(16):1935-45 - PubMed
  39. Biochem Pharmacol. 1996 Jul 26;52(2):237-45 - PubMed
  40. J Environ Pathol Toxicol Oncol. 2013;32(2):131-9 - PubMed
  41. Cancer Res. 1997 Aug 15;57(16):3465-70 - PubMed

Publication Types